<DOC>
	<DOCNO>NCT00885365</DOCNO>
	<brief_summary>The objective study demonstrate Tobrineb®/Actitob®/Bramitob® non-inferior TOBI® primary efficacy variable , forced expiratory volume one second ( FEV1 ) percent predict normal , compare safety participant cystic fibrosis chronic infection lung Pseudomonas aeruginosa .</brief_summary>
	<brief_title>A Study Comparing Efficacy Tolerability Tobrineb®/Actitob®/Bramitob® Versus TOBI®</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Patients either sex age ≥ 6 ; Clinical diagnosis cystic fibrosis define : ( 1 ) Patients preferably register National Registry CF ( document depend country legislation ) ; ( 2 ) Evidence two typical pulmonary clinical feature observe CF , e.g. , persistent colonization/infection typical CF pathogen , chronic cough sputum production , persistent chest radiography abnormality , airway obstruction , nasal polyp and/or digital clubbing ; Positive response standard sweat test ( sweat chloride concentration ≥ 60 mmol/l standard method ≥ 80 mmol/L microduct technique ) document clinical record and/or gene mutation document clinical record ; Chronic colonization P. aeruginosa : presence sputum throat culture minimum 2 positive sample P. aeruginosa previous 12 month and/or presence two precipitate antibody P. aeruginosa ; Sputum contain P. aeruginosa susceptible tobramycin ( define zone diameter ≥ 16 mm test 10 µg tobramycin disk minimal inhibition concentration base microdilution test system ) identify local laboratory screen visit ; Forced expiratory volume 1 sec ( FEV₁ ) ≥ 40 % ≤ 80 % predict normal value ; Written inform consent obtain parents/legal representative accord local regulation ) patient ( appropriate ) . Administration antipseudomonal antibiotic therapy route previous 4 week ; Evidence impair renal function ( serum creatinine level ≥ 1.5 mg/dl ) ; Evidence impair auditory function ( auditory threshold either ear 20 dB frequency 250 8000Hz ) ; Sputum culture contain Burkholderia cepacia ; Patients endstage lung disease , candidate heartlung transplantation ; History clinically significant cardiac , renal , neurological , gastrointestinal , hepatic endocrine disease relate cystic fibrosis , whose sequelae and/or treatment interfere result present study ; Female subject : pregnant active desire pregnant , lactate mother lack efficient contraception subject childbearing potential ( i.e. , contraceptive method rod contain hormone prevents user get pregnant place skin , syringe contain contraceptive hormone , combine birth control pill , i.e. , contain two hormone , intrauterine device ( IUDs ) sexual abstinence ) . A pregnancy test urine carry woman fertile age screen last clinic visit ; Known hypersensitivity aminoglycosides ; Patients evidence alcohol drug abuse , likely compliant study protocol likely compliant study treatment ; Participation another clinical trial investigational drug four week precede screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>P. aeruginosa</keyword>
	<keyword>tobramycin</keyword>
</DOC>